Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

Genetic Reasons to Walk the Extra Mile to Prevent Prostate Cancer.

Journal article

Bratt O. and Lamb AD., (2018), Eur Urol

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer.

Journal article

Sathianathen NJ. et al, (2018), Cochrane Database Syst Rev, 10

Pathologist Assessment of Novel Histological Features in Prostate Cancer

Conference paper

Tupper PM. et al, (2018), JOURNAL OF PATHOLOGY, 246, S42 - S42

Diagnostic Pathways for Screen-detected Prostate Cancer: The Plot Thickens.

Journal article

Hamdy FC. et al, (2017), Eur Urol

Orient Expression: Solving the Mystery of Asian Prostate Cancer?

Journal article

Lamb AD. et al, (2017), Eur Urol

Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary.

Journal article

Lamb AD. et al, (2017), Eur Urol Focus, 3, 328 - 329

Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer

Journal article

Sathianathen NJ. et al, (2017), Cochrane Database of Systematic Reviews, 2017

The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.

Journal article

Sathianathen NJ. et al, (2017), Future Oncol, 13, 1801 - 1807

Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.

Journal article

Johnston TJ. et al, (2017), Eur Urol, 71, 381 - 388

Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel.

Journal article

Thomas BC. et al, (2016), Endocr Relat Cancer, 23, 797 - 812

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Journal article

Shaw GL. et al, (2016), Eur Urol, 70, 214 - 218

Load More